000301922 001__ 301922
000301922 005__ 20250615021103.0
000301922 0247_ $$2doi$$a10.1016/j.esmoop.2025.105293
000301922 0247_ $$2pmid$$apmid:40494040
000301922 0247_ $$2altmetric$$aaltmetric:177955286
000301922 037__ $$aDKFZ-2025-01192
000301922 041__ $$aEnglish
000301922 082__ $$a610
000301922 1001_ $$aVancoppenolle, J.$$b0
000301922 245__ $$aFinancial toxicity and socioeconomic impact of cancer in Europe.
000301922 260__ $$a[London]$$bElsevier$$c2025
000301922 3367_ $$2DRIVER$$aarticle
000301922 3367_ $$2DataCite$$aOutput Types/Journal article
000301922 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1749647425_18023
000301922 3367_ $$2BibTeX$$aARTICLE
000301922 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301922 3367_ $$00$$2EndNote$$aJournal Article
000301922 520__ $$aEven with universal health care, patients living with cancer often face substantial treatment-related costs and income loss in Europe. Insights into the socioeconomic impact of cancer within and across countries are needed to create awareness, inform policy, and develop targeted measurement instruments. The SEC study aims to explore the socioeconomic impact and financial toxicity of cancer and identify vulnerable patient groups across Europe.To investigate experiences of a large number of patients, data were collected in a collaborative effort of hospitals and patient organizations across Europe through convenience sampling. Patients undergoing treatment currently or treated within the past 2 years could participate. A 44-item survey was developed to measure the socioeconomic impact following a cancer diagnosis. The primary outcome was the level of financial toxicity, measured by the Financial Index of Toxicity (FIT) score. To identify vulnerable groups, multiple regression analyses were used to investigate the association between the FIT score, clinical characteristics, and socioeconomic demographics, including cancer type, employment status, and country of residence.A total of 2507 patients across Europe met the inclusion criteria. Fifty-six percent of the patients reported income loss and 86% additional treatment-related expenses. Sixteen percent of patients delayed or avoided medical visits, buying medication, surgery, or other health services. Next to a significant association of the country of residence, our regression models demonstrated that divorced, self-employed patients who were younger (-0.02; P = 0.000) and lower educated (0.75; P = 0.000) with a lower household income (1.21; P = 0.000) and children (0.21; P = 0.000) at the time of diagnosis reported significantly higher FIT scores compared with older patients who were married (-0.56; P = 0.000), retired (-1.55; P = 0.000), or employed (-0.56; P = 0.000).In every European Union country, a substantial number of patients with cancer report serious financial consequences and stress. Further research is critical to inform well-tailored policies and interventions to limit the socioeconomic impact on patients with cancer.
000301922 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000301922 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301922 650_7 $$2Other$$aEurope
000301922 650_7 $$2Other$$afinancial toxicity
000301922 650_7 $$2Other$$aincome loss
000301922 650_7 $$2Other$$anon-treatment adherence
000301922 650_7 $$2Other$$aoncology
000301922 650_7 $$2Other$$asocioeconomic impact
000301922 7001_ $$aFranzen, N.$$b1
000301922 7001_ $$aAzarang, L.$$b2
000301922 7001_ $$aJuslin, T.$$b3
000301922 7001_ $$aKrini, M.$$b4
000301922 7001_ $$aLubbers, T.$$b5
000301922 7001_ $$aMattson, J.$$b6
000301922 7001_ $$aMayeur, D.$$b7
000301922 7001_ $$aMenezes, R.$$b8
000301922 7001_ $$aSchmitt, J.$$b9
000301922 7001_ $$aScotte, F.$$b10
000301922 7001_ $$aSeoane López, O.$$b11
000301922 7001_ $$aSkaali, T.$$b12
000301922 7001_ $$0P:(DE-He78)7586e13ade56c5b4d4cba2fc411b0cf0$$aUbels, J.$$b13$$udkfz
000301922 7001_ $$0P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf$$aSchlander, M.$$b14$$udkfz
000301922 7001_ $$aRetel, V.$$b15
000301922 7001_ $$avan Harten, W. H.$$b16
000301922 7001_ $$aEconomics, OECI Working Group Health$$b17$$eCollaboration Author
000301922 773__ $$0PERI:(DE-600)2844985-X$$a10.1016/j.esmoop.2025.105293$$gVol. 10, no. 6, p. 105293 -$$n6$$p105293$$tESMO open$$v10$$x2059-7029$$y2025
000301922 909CO $$ooai:inrepo02.dkfz.de:301922$$pVDB
000301922 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7586e13ade56c5b4d4cba2fc411b0cf0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000301922 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000301922 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000301922 9141_ $$y2025
000301922 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bESMO OPEN : 2022$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:49:18Z
000301922 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:49:18Z
000301922 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:49:18Z
000301922 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bESMO OPEN : 2022$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-30
000301922 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-30
000301922 9201_ $$0I:(DE-He78)C100-20160331$$kC100$$lGesundheitsökonomie$$x0
000301922 980__ $$ajournal
000301922 980__ $$aVDB
000301922 980__ $$aI:(DE-He78)C100-20160331
000301922 980__ $$aUNRESTRICTED